Radiation plus anlotinib for HER2-negative breast cancer brain metastases
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether adding anlotinib (a targeted therapy) to standard radiation can better control breast cancer that has spread to the brain. It is for people with HER2-negative breast cancer and at least one brain tumor seen on MRI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- Your breast cancer is HER2-negative (confirmed by a test on a biopsy or surgical sample).
- You have at least one brain tumor that can be measured on a contrast MRI.
- You are able to care for yourself most of the day (KPS score of 60–70 or higher).
- Your blood counts and liver/kidney function meet minimum levels (no blood transfusions or growth factors in the last 2 weeks).
- If you have had cancer treatment before (not including brain-directed therapy), at least 2 weeks have passed and any side effects have mostly resolved.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
This trial tests whether combining Anlotinib (a targeted drug that blocks tumor blood vessel growth) with whole-brain radiation can better control brain metastases in small cell lung cancer patients. It is for people with up to 10 brain tumors who have not had brain radiation before.
This study tests a new drug (SHR-A1811) combined with radiation therapy for breast cancer that has spread to the brain. The goal is to see if this combination can help control the brain tumors and possibly improve outcomes.
This study is testing a new targeted therapy for people with HER2-positive breast cancer that has spread to the brain. It aims to see if the drug can help shrink brain tumors and improve outcomes for two groups: those with cancer in the fluid around the brain and those without.
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.